FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890859706> ?p ?o ?g. }

• W2890859706 abstract "7037 Background: The purine nucleoside analogues fludarabine and clofarabine are effective agents in the treatment of acute myeloid leukemia (AML). This study evaluated the efficacy and safety of combining idarubicin and cytarabine with either clofarabine (CIA) or fludarabine (FIA) in adults with newly diagnosed AML. Methods: Using a Bayesian adaptive design, patients (pts) deemed suitable for intensive chemotherapy were randomized to receive CIA (n = 106) or FIA (n = 76). All pts received idarubicin 10 mg/m 2 IV daily on Days 1-3 and cytarabine 1 g/m 2 IV daily on Days 1-5. Clofarabine and fludarabine were given at 15 mg/m 2 and 30 mg/m 2 , respectively, IV daily on Days 1-5. Pts with FLT3 mutations could receive sorafenib. Up to 6 cycles of consolidation were allowed for responding pts. Results: Baseline characteristics were similar comparing CIA to FIA with a median age of 53 years (range, 20-66) vs 49 years (range, 18-66) respectively and ELN risk intermediate-2/adverse of 57% and 58% respectively. With a median follow-up of 27 months (range, 1-58), the CIA and FIA arms had a similar CR/CRp rate (80% and 82%, respectively). MRD negativity rate by multiparameter flow cytometry at the time of CR/CRp was higher comparing CIA to FIA (80% vs. 65%, respectively, P = 0.07). The median EFS were 13 months and 12 months, respectively (P = 0.91), and the median OS were 24 months and not reached, respectively (P = 0.23). There were more adverse events (all grades) associated with CIA, particularly AST/ALT elevation (29% vs 4%), hyperbilirubinemia (26% vs 9%) and rash (31% vs 9%). Early mortality was similar in the 2 arms (60-day mortality: 4% for CIA vs 1% for FIA; P = 0.32). Comparing the 2 arms to a historical cohort of pts treated with IA showed similar response rates, EFS and OS excluding pts with FLT3 mutations from this analysis. However, in pts < 50 years of age, FIA was associated with improved survival compared with IA (2-year EFS rate: 58% vs 30%, P = 0.05; 2-year OS rate: 72% vs 36%; P = 0.009). Conclusions: CIA and FIA have similar efficacy in younger pts with newly diagnosed AML. FIA is associated with a better toxicity profile and may improve survival compared to IA in pts < 50 years of age. Clinical trial information: NCT01289457." @default.
• W2890859706 created "2018-09-27" @default.
• W2890859706 creator A5000750846 @default.
• W2890859706 creator A5006104041 @default.
• W2890859706 creator A5007886575 @default.
• W2890859706 creator A5010786159 @default.
• W2890859706 creator A5015101485 @default.
• W2890859706 creator A5020340537 @default.
• W2890859706 creator A5021380291 @default.
• W2890859706 creator A5022647201 @default.
• W2890859706 creator A5024454882 @default.
• W2890859706 creator A5055045706 @default.
• W2890859706 creator A5057822243 @default.
• W2890859706 creator A5059600583 @default.
• W2890859706 creator A5061026876 @default.
• W2890859706 creator A5074389270 @default.
• W2890859706 creator A5084290698 @default.
• W2890859706 creator A5088307376 @default.
• W2890859706 creator A5090435894 @default.
• W2890859706 creator A5091492845 @default.
• W2890859706 date "2017-05-20" @default.
• W2890859706 modified "2023-10-15" @default.
• W2890859706 title "Idarubicin and cytarabine with clofarabine or fludarabine in adults with newly diagnosed acute myeloid leukemia: Updated results of a randomized phase II study." @default.
• W2890859706 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.7037" @default.
• W2890859706 hasPublicationYear "2017" @default.
• W2890859706 type Work @default.
• W2890859706 sameAs 2890859706 @default.
• W2890859706 citedByCount "0" @default.
• W2890859706 crossrefType "journal-article" @default.
• W2890859706 hasAuthorship W2890859706A5000750846 @default.
• W2890859706 hasAuthorship W2890859706A5006104041 @default.
• W2890859706 hasAuthorship W2890859706A5007886575 @default.
• W2890859706 hasAuthorship W2890859706A5010786159 @default.
• W2890859706 hasAuthorship W2890859706A5015101485 @default.
• W2890859706 hasAuthorship W2890859706A5020340537 @default.
• W2890859706 hasAuthorship W2890859706A5021380291 @default.
• W2890859706 hasAuthorship W2890859706A5022647201 @default.
• W2890859706 hasAuthorship W2890859706A5024454882 @default.
• W2890859706 hasAuthorship W2890859706A5055045706 @default.
• W2890859706 hasAuthorship W2890859706A5057822243 @default.
• W2890859706 hasAuthorship W2890859706A5059600583 @default.
• W2890859706 hasAuthorship W2890859706A5061026876 @default.
• W2890859706 hasAuthorship W2890859706A5074389270 @default.
• W2890859706 hasAuthorship W2890859706A5084290698 @default.
• W2890859706 hasAuthorship W2890859706A5088307376 @default.
• W2890859706 hasAuthorship W2890859706A5090435894 @default.
• W2890859706 hasAuthorship W2890859706A5091492845 @default.
• W2890859706 hasConcept C126322002 @default.
• W2890859706 hasConcept C143998085 @default.
• W2890859706 hasConcept C2776694085 @default.
• W2890859706 hasConcept C2776755627 @default.
• W2890859706 hasConcept C2777198975 @default.
• W2890859706 hasConcept C2778041864 @default.
• W2890859706 hasConcept C2778397455 @default.
• W2890859706 hasConcept C2778461978 @default.
• W2890859706 hasConcept C2778729363 @default.
• W2890859706 hasConcept C2779117419 @default.
• W2890859706 hasConcept C2779263901 @default.
• W2890859706 hasConcept C2779282312 @default.
• W2890859706 hasConcept C71924100 @default.
• W2890859706 hasConceptScore W2890859706C126322002 @default.
• W2890859706 hasConceptScore W2890859706C143998085 @default.
• W2890859706 hasConceptScore W2890859706C2776694085 @default.
• W2890859706 hasConceptScore W2890859706C2776755627 @default.
• W2890859706 hasConceptScore W2890859706C2777198975 @default.
• W2890859706 hasConceptScore W2890859706C2778041864 @default.
• W2890859706 hasConceptScore W2890859706C2778397455 @default.
• W2890859706 hasConceptScore W2890859706C2778461978 @default.
• W2890859706 hasConceptScore W2890859706C2778729363 @default.
• W2890859706 hasConceptScore W2890859706C2779117419 @default.
• W2890859706 hasConceptScore W2890859706C2779263901 @default.
• W2890859706 hasConceptScore W2890859706C2779282312 @default.
• W2890859706 hasConceptScore W2890859706C71924100 @default.
• W2890859706 hasLocation W28908597061 @default.
• W2890859706 hasOpenAccess W2890859706 @default.
• W2890859706 hasPrimaryLocation W28908597061 @default.
• W2890859706 hasRelatedWork W1545841937 @default.
• W2890859706 hasRelatedWork W2028243878 @default.
• W2890859706 hasRelatedWork W2102751641 @default.
• W2890859706 hasRelatedWork W2212410517 @default.
• W2890859706 hasRelatedWork W2227661629 @default.
• W2890859706 hasRelatedWork W2248111575 @default.
• W2890859706 hasRelatedWork W2297398542 @default.
• W2890859706 hasRelatedWork W2336312578 @default.
• W2890859706 hasRelatedWork W2522737562 @default.
• W2890859706 hasRelatedWork W2522830609 @default.
• W2890859706 hasRelatedWork W2528786090 @default.
• W2890859706 hasRelatedWork W2570898724 @default.
• W2890859706 hasRelatedWork W2738123701 @default.
• W2890859706 hasRelatedWork W2751595153 @default.
• W2890859706 hasRelatedWork W2755835749 @default.
• W2890859706 hasRelatedWork W2763210453 @default.
• W2890859706 hasRelatedWork W2791912193 @default.
• W2890859706 hasRelatedWork W2803992642 @default.
• W2890859706 hasRelatedWork W2889610980 @default.
• W2890859706 hasRelatedWork W3162530256 @default.
• W2890859706 isParatext "false" @default.
• W2890859706 isRetracted "false" @default.
• W2890859706 magId "2890859706" @default.
• W2890859706 workType "article" @default.